articleTop 1% cited

Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer

Journal of Clinical Oncology · 1999 · Vol. 17(5) · pp. 1474–1474

Jennet Harvey✉(The University of Texas Health Science Center at San Antonio)Gary M. Clark(The University of Texas Health Science Center at San Antonio)C. Kent Osborne(The University of Texas Health Science Center at San Antonio)D. Craig Allred(The University of Texas Health Science Center at San Antonio)

View via DOI Publisher page

Abstract

IHC is superior to the LBA for assessing ER status in primary breast cancer because it is easier, safer, and less expensive, and has an equivalent or better ability to predict response to adjuvant endocrine therapy.

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Estrogen and related hormone effectsMedicineImmunohistochemistryBreast cancerEstrogen receptorOncologyInternal medicineAdjuvant therapyAdjuvantStage (stratigraphy)Univariate analysis

MeSH terms

AdultAgedBreast NeoplasmsFemaleHumansImmunohistochemistryLigandsMiddle AgedPredictive Value of TestsPrognosisReagent Kits, DiagnosticReceptors, EstrogenStatistics as TopicBiomarkers, TumorChemotherapy, Adjuvant

Citations

2,057

FWCI

12.01

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers